AVILEX PHARMA ApS
CVR 34896828 · Private limited company (ApS) · Active · Very high risk
AVILEX PHARMA ApS is a Private limited company (ApS), founded on , based in København Ø. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 24.0% over the next 12 months, which is 17.1 times the average for Danish companies. 13 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -10.8m and a net result of DKK -4.5m. CEO: Kristian Strømgaard.
Bankruptcy risk for AVILEX PHARMA ApS
17.1 × the average (1.41%) · higher risk than 100% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34896828
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (13 years)
- Address
- Jagtvej 162
2100 København Ø - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 469k
- Employees
- 3 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 13 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -58.7% |
| Current ratio | 472% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 3 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 0 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Net profit | DKK -4.5m | DKK -4.4m |
| Equity | DKK -10.8m | DKK -6.3m |
| Total assets | DKK 18.4m | DKK 21.6m |
| Cash | DKK 16.9m | – |
| Short-term debt | DKK 3.9m | – |
| Avg. employees | 2 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 202 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 176 | ||
| 1 Jan 2023 – 31 Dec 2023 | 155 | ||
| 1 Jan 2022 – 31 Dec 2022 | 186 | Late | |
| 1 Jan 2021 – 31 Dec 2021 | 122 | ||
| 1 Jan 2020 – 31 Dec 2020 | 109 | ||
| 1 Jan 2019 – 31 Dec 2019 | 121 | ||
| 1 Jan 2018 – 31 Dec 2018 | 151 | ||
| 1 Jan 2017 – 31 Dec 2017 | 151 | ||
| 1 Jan 2016 – 31 Dec 2016 | 151 | ||
| 1 Jan 2015 – 31 Dec 2015 | 140 | ||
| 1 Jan 2014 – 31 Dec 2014 | 153 | ||
| 27 Dec 2012 – 31 Dec 2013 | 157 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Kristian Strømgaard | Current | |
| CEO | Nanna Liebach Lüneborg | ||
| Board | Kristian Strømgaard | Current | |
| Board | Raymond George Hill | Current | |
| Board | Jonathan Mark Treherne | Current | |
| Board | Camilla Petrycer Hansen | Current | |
| Board | Anders Bach | ||
| Board | Ingelise Saunders | ||
| Board | Raymond George Hill | ||
| Board | Henrijette Elsebeth Richter | ||
| Board | Bobby G Soni | ||
| Board | Emmanuelle Coutanceau | ||
| Board | Emmanuelle Coutanceau | ||
| Board | Morten Døssing | ||
| Owner (5%) | MIKAEL SØNDERGÅRD THOMSEN ApS | Current | |
| Owner (20%) | KRISTIAN STRØMGAARD HOLDING ApS | Current | |
| Owner (10%) | Anders Bach ApS | Current | |
| Owner (50%) | Novo Holdings A/S | Current | |
| Owner (10%) | KRISTIAN STRØMGAARD HOLDING ApS | ||
| Owner (10%) | Anders Bach ApS | ||
| Owner (67%) | Novo Holdings A/S | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (5%) | KRISTIAN STRØMGAARD HOLDING ApS | ||
| Owner (5%) | Mikael Søndergaard Thomsen | ||
| Owner (10%) | Kristian Strømgaard | ||
| Owner (5%) | Anders Bach ApS | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | EY Danmark A/S | ||
| Auditor | ERNST & YOUNG DENMARK P/S | ||
| Auditor | EY Godkendt Revisionspartnerselskab | ||
| Auditor | Grant Thornton, Godkendt Revisionspartnerselskab | ||
| Auditor | Beierholm Godkendt Revisionspartnerselskab | ||
| Founder | Anders Bach | Current |
The CEOs' other companies
Kristian Strømgaard – 5 other companies
- ConradSeverin Holding ApS Active
- EmmaMadeline Holding ApS Active
- KRISTIAN STRØMGAARD HOLDING ApS Active
- Neurophase Therapeutics ApS Active
- Strømgaard Invest ApS Active
Nanna Liebach Lüneborg – 6 other companies, of which 1 bankrupt
- IO BIOTECH ApS Bankrupt 8 Apr 2026
- AFFINICON ApS Opløst
- Forbion Nordics ApS Active
- MINERVAX ApS Active
- PCOVERY ApS Opløst
- Strategic Partners A/S Active
Address history (3 moves)
| Jagtvej 162, 2100 København Ø | |
| Ole Maaløes Vej 3, 2200 København N | |
| c/o Kristian Strømgaard, Jagtvej 162, 2100 København Ø | |
| Ole Maaløes Vej 3, 2200 København N |
Employees per year
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about AVILEX PHARMA ApS
Has AVILEX PHARMA ApS gone bankrupt?
No, AVILEX PHARMA ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of AVILEX PHARMA ApS?
Our model estimates a bankruptcy risk of 24.0% over the next 12 months (very high risk), which is 17.1 times the average for Danish companies.
Who is the CEO of AVILEX PHARMA ApS?
Kristian Strømgaard is the CEO of AVILEX PHARMA ApS.
Who is the auditor of AVILEX PHARMA ApS?
AVILEX PHARMA ApS most recently used EY Godkendt Revisionspartnerselskab.
When was AVILEX PHARMA ApS founded?
AVILEX PHARMA ApS was founded on 27 December 2012.
What is the equity of AVILEX PHARMA ApS?
Equity was DKK -10.8m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.